What Happens When You Stop Taking Tirzepatide?
It's one of the most important questions patients ask — and the clinical data gives a clear, if sobering, answer. SURMOUNT-4 trial results show that most participants who stopped tirzepatide regained significant weight within a year, along with partial reversal of cardiometabolic benefits. Here's what the research shows, why it happens, and what to discuss with your provider.
Key takeaways
A post hoc analysis of SURMOUNT-4 (JAMA Internal Medicine, 2025) found that most participants who stopped tirzepatide regained at least 25% of their lost weight within one year.
Mean weight change from week 36 to week 88: +14.0% with placebo, −5.5% with continued tirzepatide.
Weight regain was associated with partial reversal of cardiometabolic improvements — blood pressure, lipids, and glycemic measures worsened in proportion to regain.
Overall mean weight reduction from week 0 to 88 was 9.9% with placebo vs 25.3% with tirzepatide — those who stopped remained below baseline, but lost most of their treatment-phase progress.
Whether to continue, reduce, or stop treatment is a clinical decision for you and your licensed provider — not one this article can make for you.
What the SURMOUNT-4 trial actually found
SURMOUNT-4 was a phase 3 randomized withdrawal trial. Participants (n = 670) received open-label tirzepatide at a maximum tolerated dose of 10mg or 15mg for a 36-week lead-in period, during which they experienced a mean weight reduction of 20.9%. They were then randomly assigned to either continue tirzepatide or switch to placebo for the following 52 weeks.
The core finding
From week 36 to week 88, participants who continued tirzepatide experienced a mean weight change of −5.5%. Participants switched to placebo experienced a mean weight regain of 14.0%.
At week 88, 89.5% of participants continuing tirzepatide had maintained at least 80% of their lead-in weight loss, compared with 16.6% of those on placebo.
Cardiometabolic benefits partially reversed
Weight regain was not the only consequence. A post hoc analysis published in JAMA Internal Medicine examined 308 participants in the placebo arm and found that the degree of weight regain corresponded to the degree of reversal in cardiometabolic parameters — including waist circumference, non–HDL cholesterol, hemoglobin A1c, and fasting insulin. Participants with the least regain saw the least reversal.
Not a complete reset
Overall mean weight reduction from week 0 to week 88 was 9.9% for the placebo group and 25.3% for the tirzepatide group. Participants who stopped remained meaningfully below their starting weight — but lost much of the reduction they had achieved during the treatment phase.
Why weight comes back after stopping
Obesity is widely characterized in the clinical literature as a chronic condition involving hormonal and neurological signals that regulate hunger, satiety, and energy expenditure — not simply a matter of eating too much or moving too little.
What tirzepatide does while you're taking it
Tirzepatide is a single molecule combining GIP and GLP-1 receptor agonism, producing effects on appetite, food intake, and metabolic function. While the medication is active, gastric emptying is slowed and appetite signals are suppressed.
What happens when it stops
When tirzepatide is discontinued, its activity at these receptors ends. Gastric emptying speeds back up, appetite signals return, and calorie intake tends to increase toward pre-treatment patterns. The physiological conditions that were being actively managed reassert themselves.
This is not a failure of willpower. It is a recognized response to discontinuing a medication that was managing an ongoing condition. Summarizing the trial, the SURMOUNT-4 investigators concluded that withdrawing tirzepatide led to substantial regain of lost weight, whereas continued treatment maintained and augmented initial weight reduction.
Weight outcomes — SURMOUNT-4 data
Data from the SURMOUNT-4 phase 3 trial (Aronne et al., JAMA, 2023) and post hoc analysis (Horn et al., JAMA Internal Medicine, November 2025). Trial results reflect group averages under study conditions; individual results vary.
Reasons patients consider stopping — and what to raise with your provider
Each of these is a conversation to have with your licensed provider, who can assess your individual situation. None of them has a single right answer.
"I reached my goal weight"
The SURMOUNT-4 data indicates that discontinuing after reaching a target weight was followed by substantial regain for most participants. Your provider can discuss what maintenance options exist and what would be appropriate in your case.
"I can't afford to continue"
Cost is a real and valid concern, and it's worth raising directly with your provider rather than stopping without telling anyone. Your provider can discuss whether any adjustment to your treatment plan is clinically appropriate.
"I'm having side effects"
If side effects are prompting you to consider stopping, contact your provider before making a change. Side effects can sometimes be addressed without full discontinuation — but that assessment needs to come from a clinician who knows your history.
"I'm planning to get pregnant"
Tirzepatide is contraindicated during pregnancy. If you are pregnant, planning to become pregnant, or think you may be pregnant, contact your provider promptly to discuss an appropriate plan.
If you and your provider decide to stop
These are general, widely-recommended health practices — not a protocol for preventing weight regain, and not a substitute for a plan made with your clinician.
- Maintain adequate protein intake. Protein supports the preservation of lean muscle mass during and after weight loss.
- Continue regular physical activity. Both resistance training and aerobic activity are consistently recommended as part of long-term weight management.
- Stay in contact with your provider. If you notice weight regain, tell your care team early rather than waiting. Options can be discussed.
- Do not restart, adjust, or re-titrate medication on your own. Any decision to resume treatment, and at what dose, must come from your licensed provider.
Frequently asked questions
What happens when you stop taking tirzepatide?
In SURMOUNT-4, participants who switched to placebo regained a mean of 14.0% of body weight over 52 weeks, while those who continued tirzepatide lost an additional 5.5%. A post hoc analysis found most participants who stopped regained at least 25% of their lost weight within one year, with cardiometabolic improvements partially reversing in proportion to regain.
Will I regain all my weight if I stop tirzepatide?
Most participants regained a significant portion but not all. Overall mean weight reduction from week 0 to 88 was 9.9% in the placebo group versus 25.3% in the continued-treatment group — meaning those who stopped remained below baseline while losing much of their treatment-phase progress.
Why do you regain weight after stopping tirzepatide?
Tirzepatide acts on GLP-1 and GIP receptors that influence appetite, food intake, and metabolic function. When it is discontinued, those effects end — gastric emptying speeds up, appetite signals return, and calorie intake tends to rise toward pre-treatment levels. This is a recognized physiological response, not a failure of willpower.
Can you stop tirzepatide gradually instead of all at once?
There is no FDA-approved tapering protocol for tirzepatide. Any change to your dosing schedule should be discussed with your licensed healthcare provider.
Is tirzepatide a long-term medication?
The SURMOUNT-4 investigators concluded that withdrawing tirzepatide led to substantial regain of lost weight, whereas continued treatment maintained and augmented initial weight reduction. Whether long-term treatment is appropriate for you is a decision for you and your licensed provider.
† This article is for educational purposes only and does not constitute medical advice. It is not guidance on whether to start, continue, or stop any medication. Data referenced from the SURMOUNT-4 phase 3 trial (Aronne et al., JAMA, 2023) and post hoc analysis (Horn et al., JAMA Internal Medicine, published online November 24, 2025; doi:10.1001/jamainternmed.2025.6112). Trial findings represent group averages under controlled study conditions and may not reflect individual outcomes. Never change or stop a prescribed medication without first consulting your licensed healthcare provider. Compounded tirzepatide available through Ondra Health is not FDA-approved and is not reviewed by the FDA for safety, effectiveness, or manufacturing quality.